[Fundamental and clinical studies on aztreonam in the gynecological field].
Aztreonam (AZT), a new monocyclic beta-lactam antibiotic was studied on clinical efficacy for infectious disease in gynecological field. At about 80 minutes following intravenous injection of 1 g dose of AZT, it penetrated well into internal genital organs at therapeutic levels. Moreover it transferred very fast and enough into intrapelvic dead space exudate, and its level was kept still as high at 12 hours after administration. AZT was given to 20 women affected with gynecological infectious disease. The outcome of AZT therapy was as follows: effective in 5 out of 6 patients (83.3%) administered intravenously and in all of 14 patients (100%) received intramuscularly. Notable adverse effects or abnormal laboratory findings were not observed except 1 case of diarrhea and 2 cases of transient and slight elevation of serum CPK and transaminases. Based on these results, we may conclude that AZT is a highly effective and a very safe antibiotic for the treatment of infectious disease in gynecological field.
D000328:Adult; D001398:Aztreonam / Q000008:administration & dosage / Q000378:metabolism* / Q000627:therapeutic use; D001424:Bacterial Infections / Q000188:drug therapy* / Q000378:metabolism; D004341:Drug Evaluation; D005260:Female; D005831:Genital Diseases, Female / Q000188:drug therapy* / Q000378:metabolism; D005836:Genitalia, Female / Q000378:metabolism*; D006801:Humans; D007263:Infusions, Parenteral; D007275:Injections, Intravenous; D008875:Middle Aged; D010388:Pelvis / Q000378:metabolism
D001398:Aztreonam